🔴 Neurosense Therapeutics is trading 5% down on September 28, 2026, amid broader risk-off market sentiment

Neurosense Therapeutics is trading at $6.60, down 5.04%, amid broader risk-off sentiment; no company-specific catalyst is confirmed.

• The shares compare with the September 25 close of $6.95.
• Context includes the U.S. rejection of Iran’s proposal, elevated Treasury yields, rising oil prices and lower major U.S. indices; a direct link is unconfirmed.
• A September 25 update reported narrower first-half losses and targeted a December 2026 Canadian filing for PrimeC, but does not explain the drop.